I N recent months makers of weight-loss drugs have gone on a crash diet. In late July Novo Nordisk, the Danish firm that gave ...

Novo Nordisk is leading the race to get an oral weight loss GLP-1 drug approved. It needs to ensure it has addressed production quality and supply chain issues. Oral Wegovy is demonstrating ...

The four-star fund is in the top 22% of its peers on a one-year basis, up 19%, versus 16.2% for the category and 19% for the ...

Bernstein reiterated its Outperform rating on Novo Nordisk, saying the company’s diabetes and obesity GLP-1 portfolio remains well-positioned following fresh data from the European Association for the ...

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

The changes come five weeks into the tenure of new CEO Maziar Mike Doustdar. Doustdar was tapped to replace Novo's previous ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s ...

Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVO’s stock dip ...

Novo Nordisk is not wasting time beginning the layoffs it announced last week as part of a major restructuring effort. The ...

Novo Nordisk ( NVO 6.38%) -- the original Ozempic stock -- jumped higher again Thursday after announcing results from a ...

Durham Technical Community College and Novo Nordisk officials broke ground this week on a new $41.2 million life sciences education center that will prepare students for careers in North Carolina's ...

Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug ...